Australia’s CSL Ltd, the world’s largest blood products company, said on Monday it had agreed to buy Novartis AG’s global influenza vaccine business for $275m, part of the Swiss drugmaker’s drive to focus on its best assets, Reuters reported. The sale of the flu business will conclude Novartis’ overhaul of its units which it had flagged in April, aimed at strengthening its cancer business and exiting underperforming operations.
